Meiji Yasuda Asset Management’s BioMarin Pharmaceuticals BMRN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $445K | Hold |
7,780
| – | – | 0.02% | 386 |
|
|
2026
Q1 | $439K | Sell |
7,780
-30
| -0.4% | -$1.75K | 0.02% | 365 |
|
|
2025
Q4 | $464K | Sell |
7,810
-1,700
| -18% | -$92.6K | 0.02% | 346 |
|
|
2025
Q3 | $515K | Sell |
9,510
-286
| -3% | -$16.4K | 0.02% | 327 |
|
|
2025
Q2 | $538K | Sell |
9,796
-2,229
| -19% | -$131K | 0.03% | 329 |
|
|
2025
Q1 | $850K | Sell |
12,025
-530
| -4% | -$35.7K | 0.03% | 332 |
|
|
2024
Q4 | $825K | Sell |
12,555
-34
| -0.3% | -$2.28K | 0.03% | 347 |
|
|
2024
Q3 | $885K | Sell |
12,589
-48
| -0.4% | -$4.01K | 0.03% | 327 |
|
|
2024
Q2 | $1.04M | Buy |
12,637
+5,731
| +83% | +$477K | 0.04% | 304 |
|
|
2024
Q1 | $603K | Sell |
6,906
-8,542
| -55% | -$765K | 0.03% | 393 |
|
|
2023
Q4 | $1.49M | Buy |
15,448
+310
| +2% | +$27.4K | 0.07% | 264 |
|
|
2023
Q3 | $1.34M | Buy |
15,138
+7,520
| +99% | +$669K | 0.06% | 281 |
|
|
2023
Q2 | $660K | Sell |
7,618
-82
| -1% | -$7.72K | 0.03% | 349 |
|
|
2023
Q1 | $749K | Sell |
7,700
-7,711
| -50% | -$799K | 0.04% | 329 |
|
|
2022
Q4 | $1.59K | Sell |
15,411
-20
| -0.1% | -$1.88K | 0.08% | 263 |
|
|
2022
Q3 | $1.31M | Buy |
15,431
+1,600
| +12% | +$142K | 0.08% | 272 |
|
|
2022
Q2 | $1.15M | Buy |
13,831
+100
| +0.7% | +$7.96K | 0.07% | 296 |
|
|
2022
Q1 | $1.06M | Sell |
13,731
-240
| -2% | -$20.1K | 0.06% | 316 |
|
|
2021
Q4 | $1.23M | Buy |
13,971
+4,800
| +52% | +$396K | 0.08% | 239 |
|
|
2021
Q3 | $709K | Hold |
9,171
| – | – | 0.05% | 312 |
|
|
2021
Q2 | $765K | Sell |
9,171
-170
| -2% | -$13.5K | 0.04% | 305 |
|
|
2021
Q1 | $705K | Buy |
9,341
+930
| +11% | +$76K | 0.05% | 291 |
|
|
2020
Q4 | $738K | Buy |
8,411
+4,150
| +97% | +$329K | 0.07% | 233 |
|
|
2020
Q3 | $324K | Sell |
4,261
-1,330
| -24% | -$135K | 0.04% | 298 |
|
|
2020
Q2 | $690K | Buy |
+5,591
| New | +$556K | 0.07% | 249 |
|
|
2020
Q1 | – | Sell |
-2,391
| Closed | -$202K | – | 319 |
|
|
2019
Q4 | $202K | Buy |
+2,391
| New | +$181K | 0.02% | 489 |
|
|
2019
Q3 | – | Sell |
-2,391
| Closed | -$205K | – | 486 |
|
|
2019
Q2 | $205K | Buy |
+2,391
| New | +$205K | 0.02% | 489 |
|
|
2018
Q4 | – | Sell |
-2,101
| Closed | -$204K | – | 466 |
|
|
2018
Q3 | $204K | Buy |
+2,101
| New | +$210K | 0.02% | 483 |
|
Other funds holding BMRN
VPC
Meiji Yasuda Asset Management's BMRN Position: Q2 2026 in Review
Meiji Yasuda Asset Management held its BioMarin Pharmaceuticals (BMRN) position steady in Q2 2026 at 7,780 shares worth $445K. The position accounts for 0.02% of the portfolio, ranked #386.
Meiji Yasuda Asset Management first reported a position in BMRN in Q3 2018 and has held it in 28 quarters since. The position peaked at $1.49M in Q4 2023. 562 funds tracked by Wall St. Rank hold BMRN as of Q2 2026.
- Meiji Yasuda Asset Management held 7,780 shares of BioMarin Pharmaceuticals worth $445K as of Q2 2026.
- Meiji Yasuda Asset Management left its BioMarin Pharmaceuticals share count unchanged in Q2 2026.
- BioMarin Pharmaceuticals made up 0.02% of Meiji Yasuda Asset Management's portfolio in Q2 2026, its #386 holding.
- Meiji Yasuda Asset Management first reported a position in BioMarin Pharmaceuticals in Q3 2018 and has held it in 28 quarters since.
- Meiji Yasuda Asset Management's BioMarin Pharmaceuticals position peaked at $1.49M in Q4 2023.
- 562 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2026.
Based on Meiji Yasuda Asset Management's 13F filing for Q2 2026, filed 13 Aug 2026.